A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.
about
Supervised dosing with a long acting opioid medication in the management of opioid dependenceManagement of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technologyRecognizing Potential Buprenorphine Medication Misuse: Product Packaging Does Not Degrade With Laundering.Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia.Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.Quantitative determination of buprenorphine, naloxone and their metabolites in rat plasma using hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry.Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusersEffect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.Buprenorphine implants in medical treatment of opioid addiction.Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment.Maintainence Treatment of Opioid Dependence with Tramadol.Ischemic Hand Complications From Intra-Arterial Injection of Sublingual Buprenorphine/Naloxone Among Patients With Opioid Dependency.Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary.Advances in the delivery of buprenorphine for opioid dependence.Treatment of opioid dependence with buprenorphine: current update.Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.Management of opioid use disorders: a national clinical practice guideline.Perceptions and practices addressing diversion among US buprenorphine prescribers.Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective.Suboxone: Rationale, Science, Misconceptions.Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.Understanding the Agent, Part III: Specific DrugsBuprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinionsMySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot studyEmpirical Studies Addressing the Opioid Epidemic: An Urgent Call for Research
P2860
Q24187551-2E41FDC4-FAF8-494B-AA7D-3957DBFF6D12Q28080140-4CAF86D8-A47F-4788-BCAE-1C18BE7B62BBQ30300304-CC63C551-E357-4957-B707-C427CCA6B158Q33584358-F9D5C830-56E7-41A9-B395-A5DE314091C3Q36030715-14688A43-98C4-4AE8-951C-0C1B4E6FC259Q36030969-A9B217C2-BC16-4064-829E-0947660EAC9FQ36070644-98FCF9EF-7203-4900-B699-6FD9D28FFC30Q36803326-4302CEE3-0AE4-4FF4-B674-0651866B0B5BQ38374886-78F16503-8545-45BF-A2E1-EFAD35E53A31Q38379235-426FD051-4842-4019-AF23-525600FCF2E3Q38750450-5A549828-C8B5-4A1B-AD56-DF1C25ABB956Q40450431-BB8727E3-4121-40F4-A68A-7CF41615E0C0Q40991270-D20F2A3E-EF88-4BD4-A9CD-66DE39886272Q41707219-89FEF8EB-CE8B-4F4B-B95A-B86CC75BFBAFQ43061554-66DF8CE6-9A6C-4033-B7D5-B3A7BBAACFA2Q43142523-746D2D99-7988-42D9-842B-A8D03F958DBEQ44348609-09988586-5055-47FB-8A8C-4212DD83CEA6Q45946172-E0AD6D9E-2587-4634-96BD-616FA25A607DQ47133543-A1A36366-9E9C-4582-AF1C-01EEF41C74E3Q47693045-0690B85D-2149-4D41-8A58-62AC6AE5F275Q52316126-E6D978B7-B454-4C44-ACD2-3DF161A4FD02Q52316798-5A5328FC-5310-4A70-8820-F9D72B444F30Q52577389-2015CE87-6C7A-451A-929C-C7D9188D69DBQ52645984-72E3B031-7471-43B8-9C51-604D93158735Q53125417-F80F6AB5-750A-47C6-A932-B30BB3D13204Q57462909-965B8549-AD60-4093-9B0F-81796647940BQ58569574-DAAF8EAB-A935-47BA-8E69-03B858A5EC46Q58700874-E4C5DA75-4391-467B-A701-80597D027329Q58787962-BA78F201-25D3-4B33-AF42-4BCF905ECE7A
P2860
A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A review of buprenorphine dive ...... riences from around the world.
@ast
A review of buprenorphine dive ...... riences from around the world.
@en
A review of buprenorphine dive ...... riences from around the world.
@nl
type
label
A review of buprenorphine dive ...... riences from around the world.
@ast
A review of buprenorphine dive ...... riences from around the world.
@en
A review of buprenorphine dive ...... riences from around the world.
@nl
prefLabel
A review of buprenorphine dive ...... riences from around the world.
@ast
A review of buprenorphine dive ...... riences from around the world.
@en
A review of buprenorphine dive ...... riences from around the world.
@nl
P2860
P1476
A review of buprenorphine dive ...... riences from around the world.
@en
P2093
Michelle R Lofwall
Sharon L Walsh
P2860
P304
P356
10.1097/ADM.0000000000000045
P577
2014-09-01T00:00:00Z